IMA — ImageneBio, Inc.

Is IMA overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of November 17, 2026

ImageneBio, Inc. (IMA) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $3.20. The rating moved from Neutral to Oversold on November 10, 2026.

See all oversold Healthcare stocks →

AI analysis

ImageneBio, Inc. faces typical small-cap biotech dynamics: limited public disclosure and likely constrained liquidity increase sensitivity to financing, clinical and partnership news. Market-friendly sentiment toward growth names provides some near-term support, while sector-wide convertible-debt pressure and competition raise downside risks absent clear non-dilutive funding or positive binary catalysts. Monitor cash runway, upcoming clinical/regulatory milestones and any partnership or licensing announcements as primary directional drivers for the stock.

Key factors

  • Limited company-specific public disclosures and no recent EDGAR filing comparison available, constraining visibility into near-term financial runway and milestones.
  • Risk-on market tone and growth-focused flows can support small-cap biotech upside around positive clinical/partnership updates.
  • Sector theme of convertible-debt financing in diagnostics/biotech increases potential dilution pressure across the group, which can compress multiples for issuers without clear cash runway.
  • Competitive dynamics in biopharma and shifting care models (outpatient/home treatment trends) may create partnering or commercial opportunities if pipeline assets align with those themes.
  • Liquidity and trading volume likely limited vs. large-cap peers, increasing idiosyncratic price volatility around news.
  • Catalyst-driven upside possible from clinical readouts, regulatory events, or partnership/M&A interest.

Risks

  • Cash runway and financing risk: need for capital raises or dilutive convertible debt could materially impact equity value.
  • Clinical and regulatory binary risk: trial setbacks or regulatory delays would have outsized negative effects.
  • Market liquidity and volatility: thin trading can amplify price moves and widen bid/ask spreads.
  • Competitive risk: larger pharma or better-capitalized rivals could outcompete or limit commercial opportunities.
  • Macro and sector rotation: defensive flows into large-cap pharma or away from small-cap biotech could pressure shares despite company-specific progress.
  • Execution risk: shortcomings in commercialization, partnerships, or operational execution could impair growth prospects.

See today's live rating, score and targets

Members see the live hourly rating for IMA — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.